Skip to Content
Contact DCTD
Show menu
Search this site
Last Updated: 06/01/2023

2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Schedule of DCTD Presentations

DCTD-supported research will be presented at the ASCO Annual Meeting External Link from June 2-6, 2023. The following tables include the oral and poster sessions containing DCTD staff speakers and co-authors.

Oral Sessions

Title Link
SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL) Plenary Session External Link
June 4/2:53 pm CDT
Innovative Solutions to the Challenges of Cancer Clinical Trials: FDA and NCI perspectives

NCI Speakers: James Doroshow, Monica Bertagnolli, Sheila Prindiville
Education Session External Link
June 5/10:45-12:00 pm CDT

Poster Sessions

eePublication; OAOral Abstract Session; PPoster Presentation; PDPoster Discussion Session

Title Link
Abstract #
Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials P1565 External Link
Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609) OA2504 External Link
Blood-based assessment of patients with mismatch repair-deficient tumors enrolled in NCI-MATCH Arm Z1D (nivolumab) P2560 External Link
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas P3022 External Link
Molecular profiling of ctDNA from NCI-MATCH patients enrolled for treatment with mTOR1/2 inhibitor sapanisertib (arm M) and the Hedgehog pathway inhibitor vismodegib (arm T) P3047 External Link
Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2 P3108 External Link
Discovery of gene fusions in driver-negative NCI-MATCH screening samples P3112 External Link
A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer P4044 External Link
Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses PD5512 External Link
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers PD5517 External Link
Phase 2 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with granulosa cell ovarian cancer

Presenter: Sarah Shin, MD
P5564 External Link
Gynecologic-cancer analysis of ARID1A alterations detected in tissue and liquid biopsies P5593 External Link
Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance) OA7500 External Link
Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466) OA9511 External Link
Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG Pediatric MATCH trial Arm I (APEC1621I) OA10006 External Link
Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B) OA10007 External Link
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27) PD11516 External Link
PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network study P11527 External Link
ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma P11531 External Link
A phase 2 study of an anti-PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma P11533 External Link
Longitudinal follow-up and outcomes of pediatric and adult patients with SDH-deficient GIST P11542 External Link
A Lasso Cox score consisting of CTLA4+ regulatory T cells (Treg), monocytic myeloid derived suppressor cells (M-MDSC), and CXCR3+ CD8+ T cells: Association with adjuvant ipilimumab (ipi) survival outcomes in patients (pts) with high-risk melanoma eE21557 External Link
Expanding eligibility criteria for renal and liver function in NCI-sponsored immunotherapy clinical trials eE13610 External Link
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with refractory gallbladder cancer (cohort 48) eE16330 External Link
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001 PTPS4198 External Link
A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects. PTPS4607 External Link
A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress PTPS5110 External Link
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 PTPS9603 External Link
Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors PTPS10066 External Link
Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers PTPS10071 External Link

Staff Kiosk Schedule — Booth #6034

Date Time Presenter
June 3 9:00 AM - 11:00 AM
3:00 - 5:00 PM
Aniruddha Ganguly, PhD
Cancer Diagnosis Program
June 4 9:00 AM - 11:00 AM Sharad Verma, PhD
Developmental Therapeutics Program
11:00 AM - 1:00 PM Aniruddha Ganguly, PhD
Cancer Diagnosis Program
1:00 PM - 3:00 PM Marc S. Ernstoff, MD
Developmental Therapeutics Program
June 5 11:00 AM - 1:00 PM Aniruddha Ganguly, PhD
Cancer Diagnosis Program
1:00 PM - 3:00 PM Lokesh Agrawal, PhD
Cancer Diagnosis Program
3:00 - 5:00 PM Aniruddha Ganguly, PhD
Cancer Diagnosis Program